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Abstract. Screening and treatment of sexually transmissible infections, including HIV, are free in the UK nations; pre-
exposure prophylaxis (PrEP) became free in England in October 2017 through the PrEP Impact trial. Doctor-led PrEP
clinics started at 56 Dean Street in September 2015, with the drug purchased privately at full price. The service was
expanded to other staff to support initiation and monitoring of increasing numbers of attendees purchasing PrEP from
online pharmacies. Nonetheless, when the clinic was given a target of 1700 for the PrEP Impact trial, it was clear this could
not be achieved in a timely manner through 56 Dean Street alone. To prepare for the trial, all staff with HIV testing
competencies were trained in good clinical practice and trial-speciﬁc procedures, and a patient group directive was
approved to facilitate nurse prescribing and dispensing. Electronic pro formas to capture eligibility for starting or
continuing PrEP were adapted for the Dean Street Express clinic, with some information collected directly from service
users using touch screens. These interventions, together with an update to the 2016 information leaﬂet developed by
the community, enabled enrolment and follow-up of 1700 participants in 4 months. PrEP advice and monitoring were
easily accommodated in the 56 Dean Street sexual health service, but did require additional training and approval for nurse
prescribing and dispensing drug in order to achieve the target, which still fell short of the demand.
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Introduction
Context for model of care
Sexual health care in England is commissioned by local
authorities and delivered through approximately 200 sexual
health clinics that are afﬁliated with National Health Service
(NHS) hospitals, community health services or commercial
organisations. HIV care is commissioned by NHS England
and delivered in most of these clinics.
The 56 Dean Street (56DS) clinic, a satellite of Chelsea
and Westminster NHS Foundation Trust, is a combined sexual
health and HIV service located in Soho, central London, UK.
The clinic provides free, conﬁdential and comprehensive
diagnosis and management of sexually transmissible infections
(STIs), contraception and out-patient care to those diagnosed
with HIV infection as well as viral hepatitis, referring to Chelsea
and Westminster hospital if admission is required.
The service moved to its present location in 2009. Since
opening, attendances for asymptomatic STI screening have
risen year on year and, in order to increase clinic capacity,
56DS opened a new service, Dean Street Express (DSE), in
February 2014. DSE is located at 34–35 Dean Street and was
designed as a nurse-led service providing STI screening for
people without symptoms. By automating steps in the patient
pathway, the time to result notiﬁcation and the time to treatment
were reduced from a median of 7 days to 6 h, and 9 to 2 days
respectively. A full description of the model of STI screening
at DSE is provided in Whitlock et al.1 Brieﬂy, users access the
service through computer touch screens, registering with their
mobile telephone number, which generates a conﬁrmation
SMS text to access the service further. Users input their
sexual history directly into the electronic patient record
through the touch screen, and this informs the algorithm for
the generation of labels, which informs the healthcare assistant
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which specimens are required. Testing for STIs comprises
chlamydia and gonorrhoea testing performed by NAAT
(nucleic acid ampliﬁcation testing) on self-taken swabs and
urine processed on-site in a GeneXpert Inﬁnity machine
(Cepheid, Sunnyvale, CA, USA) with a 90-min turnaround
time. Blood tests for HIV, syphilis and, if needed, hepatitis
B and C are collected after a trained staff member (a nurse or
healthcare assistant) has reviewed the sexual history and
provided risk reduction advice and referral to other services
if appropriate. Blood tests are analysed in an off-site laboratory
with a 6-h turnaround. All STI results are texted directly to the
patient’s mobile telephone from the clinic computer system,
although positive HIV and hepatitis C results are communicated
by a health advisor (an individual with experience in sexual
health and HIV counselling, including adherence support,
and with responsibility for recall and partner notiﬁcation).
Since the implementation of the DSE model of care, there
has been a steady increase in daily attendances, with over
100 000 chlamydia or gonorrhoea test notiﬁcations sent to
attendees in 12 consecutive months in 2014–15. The volume
of testing attendances increased by 59% over the same
observation period, reaching a 5-day moving average of
241.0 per day at DSE.1
Description
Pre-exposure prophylaxis introduction in England
and the local problem
Oral pre-exposure prophylaxis (PrEP) as coformulated
tenofovir/emtricitabine is freely available on the NHS to those
at risk in Wales and Scotland, but not in England. Nonetheless,
there are several thousand PrEP users in England who have
purchased PrEP from online pharmacies or directly from clinics.
56DS started to offer a PrEP service in September 2015,
initially through consultant physician-led clinics to individuals
who were able to pay for their drug at cost price. The consultants
developed a PrEP guideline and provided individuals with an
information sheet and collected consent. In October 2015, two
UK-based websites were launched providing information about
PrEP: www.Prepster.info and www.iwantprepnow (accessed 4
July 2018). The latter facilitated individuals to buy generic oral
PrEP online for personal use. Due to the increase in numbers of
clinic attendees disclosing their use of generic tenofovir/
emtricitabine as oral PrEP, it was necessary to expand the
staff disciplines able to advise and monitor those sourcing
generic PrEP. To assist with this, and ensure that the key
messages were consistent whether delivered in the clinic or
community, the ﬁrst UK PrEP guide was produced in June
2016 by a collaboration of HIV journalists, UK doctors,
charities and PrEP advocates.2 In parallel, the professional
associations responsible for developing clinical guidelines for
HIV and sexual health released a practical guide and simple
ﬂow chart describing the procedures and investigations at
initiation of PrEP and quarterly follow-up.3
PrEP initiation
PrEP monitoring at 56DS can be provided by any member of
staff who sees service users, most frequently nurses, but also
doctors and healthcare assistants. At PrEP initiation, a baseline
PrEP pro forma in the electronic patient record is completed
face to face during the consultation, prompting staff to ask about
a past history of renal and bone problems, hepatitis B status and
dosing preferences. Baseline tests for HIV (fourth-generation
ELISA), serum creatinine and urine dipstick for assessment
of proteinuria, as well as tests to determine hepatitis B status,
if required, and a full screen for STIs, including chlamydia,
gonorrhoea, syphilis and, where there is risk, hepatitis C are
performed. Urine dipstick results are immediately communicated
(if protein 1+ or higher is found, a urine specimen for
protein: creatinine ratio is obtained for analysis). Blood tests
results for HIV, syphilis, hepatitis B, hepatitis C and renal
function have a turnaround time of 24 h and are reviewed by a
dedicated team of nurses and healthcare assistants. In case of
abnormalities, results are submitted to the team of doctors for
review. Chlamydia and gonorrhoea tests results are delivered
via text message to the patients within 6 h from sampling and,
in the case of any positive result, an appointment for treatment
is offered at the patient’s ﬁrst availability.
PrEP start is actively recommended in individuals with a
frequent risk of exposure to HIV, even when this is recent, but
a fourth-generation ELISA HIV test is performed on the day of
PrEP start and offered 4 weeks later.
PrEP follow-up
Those continuing on PrEP are advised to return every 3 months
for PrEP monitoring; at this visit, a follow-up pro forma
provides prompts to check for ongoing need of PrEP,
adherence, dosing preferences and to perform urinalysis,
triggering additional investigations if needed. Additional
support, practical and/or psychological, can be offered by an
experienced team of health advisors who support people living
with HIV who struggle with adherence. Anyone with a complex
medical history requiring further medical assessment can be
booked into a consultant physician-led appointment.
Interventions to scale up for PrEPxpress
In October 2017, NHS England began a 3-year implementation
trial (the PrEP Impact trial; www.prepimpact.org, accessed
4 July 2018) with a target enrolment of 10 000 at-risk
participants attending the sexual health clinics in England
and providing PrEP free of charge. The aim of the trial was
to assess how many sexual health clinic attendees require PrEP,
how many take it up and the duration of use by the study
participants. 56DS was given a target of 1700 participants and,
to accommodate this number, it was necessary to incorporate
enrolment and follow-up at DSE at no extra costs for the
commissioner. The additional costs for the hospital trust
consisted in the purchase of urine dipstick testing strips as
required for the routine management of PrEP users, the annual
creatinine tests and modiﬁcations to the touch screens to
incorporate PrEP questions. The clinic began enrolling
participants to the study on 13 October 2017, with 1700
consenting participant reached within 4 months. Such high
volume was achieved through engagement of the entire
multidisciplinary team, including doctors, nurses, health
advisors, the recall team and administrative staff. Most of
the 100-strong staff team at 56DS completed study-speciﬁc
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good clinical practice (GCP) training, which allowed them
to enrol consenting participants to the study. Clinical staff
members were already proﬁcient in providing information
about PrEP and monitoring clinic attendees, but it was
necessary to obtain approval for nurse prescribing and to
complete training for this, as well as to arrange secure
storage for the trial drug at DSE. Following the example set
by the Australian EPIC (Expanded PrEP Implementation in
Communities) trial,4 group information sessions were
performed at 56DS at hourly intervals led by a study-speciﬁc
GCP-trained staff member and a copy of the updated UK PrEP
guide2 provided to each of approximately 15 attendees.
Following the group session, each participant was
interviewed individually face to face at DSE and all 15 were
seen within a dedicated hour time slot the same day. During this
initial consultation, an online study pro forma for participants
initiating PrEP was completed and the study consent form
signed. The baseline PrEP assessment and investigations
followed the standard of care previously described, which
required the addition of a second urine bottle and serum
creatinine to the asymptomatic screening panel already in
place at DSE. Once completed, oral PrEP was prescribed
and 90 tablets dispensed according to the patient group
directive (PGD), a written protocol that enables nurse
prescribing in a hospital setting. Although this reﬂects
standard prescribing practice for STIs in sexual health
clinics, it was necessary for the hospital trust to seek legal
advice about provision of PrEP in a clinical trial. The 3-monthly
follow-up also followed the standard of care with 30, 60 or
90 tablets of oral PrEP dispensed according to need under
PGD and recorded in the study drug accountability log.
Individuals with a complex medical history, potential drug
interactions, proteinuria or abnormal creatinine, or those
who reported adverse events, were referred to a consultant
physician-led PrEP Review clinic at 56DS. Otherwise, renal
function was assessed annually through serum creatinine.
Lessons learned
Early diagnosis, treatment and partner notiﬁcation are the
cornerstones of control for STIs, which is why a free,
conﬁdential and open access service has been in place in
England for over 100 years. We have automated steps in the
patient pathway at 56DS through DSE to reduce the time to
treatment of STIs, including HIV, to 2 days.5 PrEP was
introduced informally in England through self-purchase of
drugs from online pharmacies, and the clinicians and
community worked together to ensure that this was safe by
agreeing the key messages, expanding the screening panel to
include serum creatinine and training additional staff to
advise on initiation and monitoring of PrEP as demand grew.
When the PrEP Impact study launched, further interventions
were needed to scale-up the PrEP service, and to implement
a system for nurse prescribing and dispensing drug at DSE.
This was particularly challenging because the drug was
provided through a clinical trial. After training most clinic
staff in study-speciﬁc procedures, PrEP advice and clinical
monitoring, obtaining approval for nurse prescribing in the
context of a trial and adapting the touch screens to include
PrEP questions, it was possible to enrol 1700 individuals in
4 months.
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